Javascript must be enabled to continue!
Ranibizumab for the treatment of Age-Related Macular Degeneration related research hotspot and dynamic
View through CrossRef
AbstractObjective:Bibliometric analysis in the research area of Ranibizumab and Age-Related Macular Degeneration(AMD) was conducted to describe the current trends in international research dynamics in the field and to present a visual representation of the research hotspots and difficulties in ophthalmic drugs in the last fifteen years.Method:In this cross-sectional study, bibliometrics analyzed data retrieved and extracted from the Web using the Science Core Collection (WOSCC) database to analyze the evolution and thematic trends in the delivery of studies from January 1, 2008, to September 2, 2023, for Ranibizumab and AMD studies. A total of 2691 articles on the field were assessed for specific characteristics such as year of publication, journal, author, institution, country/region, citation and keywords. Co-authorship analysis, co-occurrence analysis, co-citation analysis, and network visualization were constructed using VOSviewer. Bibliometrics identified a number of important sub-themes for further discussion and review of characterization.Results:From 2008 to 2023, the cumulative number of articles published globally increased from 1 to 2,691, with the highest number of articles published in 2020 (255 papers). RETINA THE JOURNAL OF RETINAL AND VITREOUS DISEASES published the most manuscripts (285 papers) and was cited (6,496 citations), followed by OPHTHALMOLOGY (193 papers) and GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (163 papers). OPHTHALMOLOGY was the most cited (20,865 citations), with the United States (786 papers, 38,014 citations), univ sydney (98 papers, 5,245 citations), and kim, jong woo (56 papers, 550 citations) being the most productive and influential institutions, countries, and authors, respectively.Co-occurring clusters: the top 100 keywords analyzed form 5 clusters:Marking the emerging frontiers in the field of ranibizumab and AMD. Further discussion of the 5 clusters of research is to assist the researcher in determining the scope of the research topic and planning the direction of the research.Conclusion:The number of publications and citations of research related to Ranibizumab and AMD has been increasing over the last two decades in many countries, institutions and authors. This study reveals the current trends, global collaboration patterns, basic knowledge, research hotspots and developmental trends in Ranibizumab associated with AMD research. New solutions of Ranibizumab for AMD such as shorter number of injections, prolonged drug efficacy and safety have been the major themes in the last 15 years.
Title: Ranibizumab for the treatment of Age-Related Macular Degeneration related research hotspot and dynamic
Description:
AbstractObjective:Bibliometric analysis in the research area of Ranibizumab and Age-Related Macular Degeneration(AMD) was conducted to describe the current trends in international research dynamics in the field and to present a visual representation of the research hotspots and difficulties in ophthalmic drugs in the last fifteen years.
Method:In this cross-sectional study, bibliometrics analyzed data retrieved and extracted from the Web using the Science Core Collection (WOSCC) database to analyze the evolution and thematic trends in the delivery of studies from January 1, 2008, to September 2, 2023, for Ranibizumab and AMD studies.
A total of 2691 articles on the field were assessed for specific characteristics such as year of publication, journal, author, institution, country/region, citation and keywords.
Co-authorship analysis, co-occurrence analysis, co-citation analysis, and network visualization were constructed using VOSviewer.
Bibliometrics identified a number of important sub-themes for further discussion and review of characterization.
Results:From 2008 to 2023, the cumulative number of articles published globally increased from 1 to 2,691, with the highest number of articles published in 2020 (255 papers).
RETINA THE JOURNAL OF RETINAL AND VITREOUS DISEASES published the most manuscripts (285 papers) and was cited (6,496 citations), followed by OPHTHALMOLOGY (193 papers) and GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (163 papers).
OPHTHALMOLOGY was the most cited (20,865 citations), with the United States (786 papers, 38,014 citations), univ sydney (98 papers, 5,245 citations), and kim, jong woo (56 papers, 550 citations) being the most productive and influential institutions, countries, and authors, respectively.
Co-occurring clusters: the top 100 keywords analyzed form 5 clusters:Marking the emerging frontiers in the field of ranibizumab and AMD.
Further discussion of the 5 clusters of research is to assist the researcher in determining the scope of the research topic and planning the direction of the research.
Conclusion:The number of publications and citations of research related to Ranibizumab and AMD has been increasing over the last two decades in many countries, institutions and authors.
This study reveals the current trends, global collaboration patterns, basic knowledge, research hotspots and developmental trends in Ranibizumab associated with AMD research.
New solutions of Ranibizumab for AMD such as shorter number of injections, prolonged drug efficacy and safety have been the major themes in the last 15 years.
Related Results
Long‐term visual acuity in patients with age‐related macular degeneration treated with ranibizumab and persistence of subretinal fluid
Long‐term visual acuity in patients with age‐related macular degeneration treated with ranibizumab and persistence of subretinal fluid
AbstractPurpose To analyze the visual acuity (VA) in the long term in patients with age‐related macular degeneration (ARMD) treated with ranibizumab with persistent subretinal flui...
Episcleritis following intravitreal ranibizumab injection for exudative age‐related macular degeneration
Episcleritis following intravitreal ranibizumab injection for exudative age‐related macular degeneration
Abstract Purpose Ranibizumab is a recombinant, humanized, monoclonal antibody antigen‐binding fragment that neutralizes all biologically active forms of vascular endothelial growth...
CORRELATION BETWEEN GLYCOSYLATED HAEMOGLOBIN (HBA1C) LEVEL AND MACULAR THICKNESS IN TYPE 2 DIABETIC PATIENTS IN TERTIARY CARE TEACHING HOSPITAL.
CORRELATION BETWEEN GLYCOSYLATED HAEMOGLOBIN (HBA1C) LEVEL AND MACULAR THICKNESS IN TYPE 2 DIABETIC PATIENTS IN TERTIARY CARE TEACHING HOSPITAL.
Aim : To correlate HbA1c level with macular thickness in type 2 diabetic patients to determine the impact
of blood sugar control on retina. Methods : This cross-sectional study was...
Treatment of myopic neovascularization with ranibizumab
Treatment of myopic neovascularization with ranibizumab
Abstract Purpose To determine the safety and efficacy of ranibizumab, as a treatment of choroidal neovascularization associated with pathological myopia Methods A retrospective, no...
Treatment outcome of switching from ranibizumab to aflibercept in patients with central retinal vein occlusion
Treatment outcome of switching from ranibizumab to aflibercept in patients with central retinal vein occlusion
PurposeTo describe the outcome of switching from ranibizumab to aflibercept intravitreal injections in patients with macular oedema secondary to central retinal vein occlusion (CRV...
MODIFICATION OF ADJUSTABLE MACULAR BUCKLING WITH 29-G CHANDELIER LIGHT FOR OPTIMAL POSITIONING IN HIGHLY MYOPIC EYES WITH MACULAR HOLE
MODIFICATION OF ADJUSTABLE MACULAR BUCKLING WITH 29-G CHANDELIER LIGHT FOR OPTIMAL POSITIONING IN HIGHLY MYOPIC EYES WITH MACULAR HOLE
Purpose:
To evaluate the efficacy of the modification of Adjustable Macular Buckling device in the treatment of myopic macular hole retinal detachment with posterior st...
SHORT-TERM EFFICACY OF INTRAVITREAL PATIZRA® (RANIBIZUMAB) IN TREATMENT NAIVE PATIENTS- REAL WORLD EVIDENCE IN PAKISTAN
SHORT-TERM EFFICACY OF INTRAVITREAL PATIZRA® (RANIBIZUMAB) IN TREATMENT NAIVE PATIENTS- REAL WORLD EVIDENCE IN PAKISTAN
Background: Macular oedema is a final common pathway of a multitude of both ocular and systemic insults. This study was conducted to evaluate the short-term efficacy and safety of ...
Patients With Age-related Macular Degeneration Lack Knowledge and Self-management Skills of Age-related
Patients With Age-related Macular Degeneration Lack Knowledge and Self-management Skills of Age-related
Abstract
Objective:To understand the status quo and factors influencing self-management behavior in patients with age-related macular degeneration, provide evidence for bet...

